ArticleOpen forum infectious diseases2022
Truth in DAIR: Duration of Therapy and the Use of Quinolone/Rifampin-Based Regimens After Debridement and Implant Retention for Periprosthetic Joint Infections.
Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Associations between suppressive antibiotic therapy, treatment failure, and side effects among young, immunocompetent veterans with prosthetic joint infection who undergo debridement, antibiotics, and implant retention.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2026Article
- Article
- Suppressive Antibiotic Therapy in Prosthetic Joint Infections: A Contemporary Overview.Antibiotics (Basel, Switzerland) · 2025Review
- How Often Is Rifampin Therapy Initiated and Completed in Patients With Periprosthetic Joint Infections?Clinical orthopaedics and related research · 2025Article
- Debridement, antimicrobial therapy, and implant retention (DAIR) as curative strategy for acute periprosthetic hip and knee infections: a position paper of the European Bone & Joint Infection Society (EBJIS).Journal of bone and joint infection · 2025Article
- The impact of rifampin on the efficacy of implant retention and prosthesis removal in staphylococcal periprosthetic joint infection.Frontiers in cellular and infection microbiology · 2025Article
- Variation in North American Infectious Disease Specialists' Practice Regarding Oral and Suppressive Antibiotics for Adult Osteoarticular Infections: Results of an Emerging Infections Network (EIN) Survey.Open forum infectious diseases · 2024Article
- Role of Routine Suppressive Antibiotic Therapy After Debridement, Antibiotics, and Implant Retention for Acute Periprosthetic Joint Infections.Open forum infectious diseases · 2024Article
- Appropriate Duration of Antimicrobial Treatment for Prosthetic Joint Infections: A Narrative Review.Antibiotics (Basel, Switzerland) · 2024Review
- No differences in outcomes with stopping or continuing antibiotic suppression in periprosthetic joint infections.Journal of bone and joint infection · 2024Article
- Periprosthetic Joint Infection: Current Clinical Challenges.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Debridement, Antibiotics and Implant Retention: A Systematic Review of Strategies for Treatment of Early Infections after Revision Total Knee Arthroplasty.Journal of clinical medicine · 2023Review
- Adjunctive Rifampin Following Debridement and Implant Retention for Staphylococcal Prosthetic Joint Infection: Is it Effective if not Combined With a Fluoroquinolone?Open forum infectious diseases · 2022Article
- Taking the route less traveled: on the way to COpAT.Therapeutic advances in infectious diseaseReview
- Oral Antibiotic Therapy for Shoulder Periprosthetic Joint Infection: Current and Evolving Concepts.JB & JS open accessReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Background: The optimal duration of antibiotic therapy after debridement and implant retention (DAIR) for periprosthetic joint infections (PJIs) is debated. Furthermore, the best antibiotic regimens for staphylococcal PJI are also unclear. In this study, we evaluated the impact of antibiotic therapy duration on the risk of failure. We assessed the utility of rifampin-based regimens for staphylococcal PJI managed with DAIR. Methods: We performed a retrospective cohort study of patients 18 years and older diagnosed with hip and knee PJI who underwent DAIR between January 1, 2008 and 31 December 31, 2018 at Mayo Clinic, USA. The outcome was failure of DAIR. For statistical analysis, joint-stratified Cox regression models adjusted for age, sinus tract, symptom duration, and primary/revision arthroplasty were performed. Results: We examined 247 cases of PJI with a median follow-up of 4.4 years (interquartile range [IQR], 2.3-7) after DAIR. The estimated 5-year cumulative incidence of failure was 28.1% ( Conclusions: The duration of initial IV antibiotic therapy did not correlate with treatment failure in this cohort of patients. Rifampin use is recommended for staphylococcal knee PJI. There was no apparent benefit of FQ use in staphylococcal PJI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.